Pharmaceuticals

Phase 3 trial data showed that lenacapavir was 100% effective in preventing HIV in cisgender women.

bexib
By bexib 0 Min Read

Results from the PURPOSE 1 trial showed that twice-yearly injections of lenacapavir were superior to once-daily oral Truvada for preventing HIV in cisgender women.

You Might Also Like

Imfinzi plus pre-operative chemotherapy shows significant benefit in event-free survival in the treatment of resectable non-small cell lung cancer

Eliminating maternal health disparities and driving change

Study shows potential of psilocybin as an antidepressant compared to non-psychoactive drugs

Pharma Pulse 9/10/24: Why satellite sites outperform decentralized models, number of people with clinical indications for GLP-1 drugs, and more

Pharma Pulse 5/14/24: Low investment in vaccine development, addressing ADHD drug shortages, etc.

Share This Article
Previous Article Grow Your Biz: 25 Ways to Promote Your Business in 2024
Next Article Bank of Japan expected to raise interest rates next month, Finance Ministry under pressure to intervene – Investorempires.com
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Progress of metal cutting technology: Innovative innovation, sustainability, and future labor
Manufacturing
Ceratizit showcases innovation, sustainability and cutting-edge solutions at IMTEX 2025
Manufacturing
Goldman launches an internal GEN AI Assistant with 10K employees
Banking
Taiwan emerges as key player in Indian machine tools market with 20.8% growth
Manufacturing